5-Amino-1MQ: What the Evidence Actually Shows

5-Amino-1MQ is sold across the longevity-supplement market as an oral capsule, marketed for fat loss and "cellular energy" through a mechanism most other compounds on this site don't share at all: it isn't a peptide, and it isn't administered like one.

What it actually is, and why it isn't on this site's calculator hub

5-Amino-1MQ (5-amino-1-methylquinolinium) is a small molecule, not a peptide — it has no amino-acid sequence. It's an inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that methylates and clears nicotinamide, the same building block cells use to make NAD+. The mechanistic pitch is that blocking NNMT redirects more nicotinamide toward NAD+ synthesis and reduces methylation-driven epigenetic changes linked to fat storage. That's a real, published cell-biology mechanism — described below — but the underlying pharmacology is also why this article doesn't come with a reconstitution calculator the way most of this site's compound pages do: as a small, stable molecule rather than a peptide, 5-Amino-1MQ is orally bioavailable, and a live check of the market confirms oral capsules are the dominant real-world form. Several sellers — including longevity-supplement brands that don't carry any other research peptide at all — sell it exclusively as an oral capsule; only a minority of research-chemical-specific vendors also list an injectable vial. Building a vial-to-syringe tool for a compound whose real-world dominant form is a capsule would misrepresent how it's actually taken, so this site doesn't.

The actual research: real, but entirely in mice

A research group at the University of Texas Medical Branch (Watowich lab) has published an active line of work on small-molecule NNMT inhibitors as an anti-obesity strategy. Their 2018 paper describes methylquinolinium-scaffold NNMT inhibitors that reduced body weight and white adipose mass in diet-induced obese mice, without affecting food intake or producing observable adverse effects¹. A 2022 follow-up study from the same group explicitly names the compound used as "5-amino-1-methylquinolinium" — confirming this is the same substance sold today — and reports that combining it with a reduced-calorie diet produced dramatic weight and adiposity loss in obese mice, rapidly normalizing their measurements to those of lean, age-matched control animals; a calorie-reduced diet alone did not achieve the same result in the same timeframe². That is a real, positive, mechanistically-grounded finding — and it is entirely a mouse result. A live, dedicated PubMed search for the exact compound name "5-amino-1MQ" returns zero results; searching by its full chemical name returns exactly three papers, all from this same research line, all in mice.

What this doesn't tell you: nothing about a human dose, or a human effect

NNMT itself is a genuinely active area of broader drug-target research — a live search turns up dozens of 2024-2026 papers on NNMT inhibition in cancer, kidney fibrosis, and metabolic disease. That broader research momentum is real, but it is not the same claim as "5-Amino-1MQ has been tested in those contexts" — most of that literature studies NNMT as a target using different inhibitor chemistries, or studies the enzyme's biology without testing any inhibitor drug at all. This article does not conflate general NNMT-target interest with evidence for the specific molecule sold as 5-Amino-1MQ. No human trial of 5-Amino-1MQ, for any use, at any dose, was located for this article — no published safety data, no published pharmacokinetics, no published effective dose in a person. Any specific milligram amount attached to a "5-Amino-1MQ protocol" online is not sourced to a human study; it can't be, because none exists.

The regulatory picture: entirely off FDA's radar

5-Amino-1MQ has never been nominated to FDA for compounding-bulk-substance review of any kind — checked live against both FDA's current 503A Bulks List (updated May 14, 2026) and its companion page tracking substances with documented safety concerns, including historically-withdrawn nominations; neither document contains any match for "1MQ," "methylquinolinium," or "5-amino." DailyMed's structured-product-label search returns zero results, confirming no FDA-approved product exists³. openFDA's FAERS adverse-event database returns zero reports⁴ — the second of this five-compound batch, alongside IGF-1 LR3, with a fully null safety-report history, which again reflects the absence of any formal use record rather than a demonstrated safety profile.

What this means if you're considering it

None of the 31 providers this site's own reviews cover sell 5-Amino-1MQ as a primary, boarded product — this site's own identity-layer research confirms it is not tagged to any reviewed seller. The mouse research behind 5-Amino-1MQ is real, mechanistically coherent, and comes from a legitimate, ongoing academic research program — a genuinely different starting point than a compound with no research behind it at all. But "real mouse data" and "tested in humans" are different claims, and this compound has only the first. If you're weighing it against other metabolically-marketed compounds this site now covers, our AOD-9604 evidence review has the opposite profile — a compound that reached and then failed a human efficacy trial, after passing six human safety trials — which makes it a more informative comparison than a reassuring one.